Cancer

Showing 15 posts of 1067 posts found.

shutterstock_349943306

Sophiris halts cancer study after patient death

June 25, 2018
Research and Development, Sales and Marketing Cancer, Sophiris, pharma, prostate cancer

Another clinical trial has been forced to a standstill as biotech firm Sophiris revealed that a patient death had prompted …

roche__tree

Roche’s Tecentriq combo extends life in untreated lung cancer

June 25, 2018
Research and Development, Sales and Marketing Cancer, Roche, lung cancer, pharma, tecentriq

Roche has unveiled new data on the efficacy of Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the …

shutterstock_141299494

Elderly cancer cases to increase 80% by 2035, says CRUK

June 21, 2018
Medical Communications, Research and Development CRUK, Cancer, Cancer Research UK, NHS, UK, pharma

A new report from Cancer Research UK has indicated that the number of UK  citizens over the age of 75 …

opdivo_1_1

BMS’ Opdivo becomes first immuno-oncology agent available in China

June 18, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, China, NSCLC, lung cancer, oncology, opdivo, pharma

Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …

rocherooflr

NICE turns down Roche’s Perjeta for post-surgery HER2-positive breast cancer

June 15, 2018
Medical Communications, Sales and Marketing Cancer, NICE, Perjeta, Roche, breast cancer, pharma

Roche’s ongoing dispute with UK health service watchdog NICE over the availability of its monoclonal antibody Perjeta (pertuzumab) on the …

astrazeneca_sign_sky

AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer

June 5, 2018
Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer

In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …

Eli Lilly’s President of Oncology to retire

June 5, 2018
Research and Development Cancer, Eli Lilly, appointment, oncology, pharma

Just as it ramps up its cancer-fighting efforts, Eli Lilly has revealed that its Senior Vice President and President of …

nektar-therapeutics

“Underwhelming” drug data devastates Nektar, shares fall by 42%

June 5, 2018
Manufacturing and Production, Research and Development ASCO, BMS, Bristol-Myers Squibb, Cancer, Nektar, bristol myers-squibb, pharma

Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …

janssen_latest_logo_on_sign_closer

Janssen debuts promising new cancer data at ASCO

June 4, 2018
Research and Development, Sales and Marketing ASCO, Cancer, J&J, JJ, Jassen, erdafitinib, imbruvica, pharma

Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …

roche

Roche’s breast, lung cancer offerings fail to impress at ASCO

June 4, 2018
Research and Development, Sales and Marketing ASCO, Cancer, Roche, breast cancer, lung cancer, pharma, taselisib, tecentriq

Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …

artificial-intelligence-2228610_640

Google AI outperforms 58 dermatologists in detecting melanoma

May 30, 2018
Research and Development AI< Google, Cancer, melanoma, pharma, skin cancer

An deep learning artificial intelligence system has demonstrated its ability to outperform over 50 human dermatologists in the detection of …

Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3

May 29, 2018
Manufacturing and Production, Research and Development Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …

jj

J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex

May 29, 2018
Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq

Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …

The Gateway to Local Adoption Series

Latest content